Revolution Medicines
Update in progressRVMD (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Revolution Medicines is a clinical-stage precision oncology company developing RAS-targeted therapies for RAS-driven cancers. Its pipeline centers on RAS(ON) inhibitors that bind RAS variants for mono or combination use, and RAS companion inhibitors that suppress cooperating pathways. Lead programs include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-9805) in trials.
Company score
- Sentiment
- 0.22
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.17
- Governance
- 0.12
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.08
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.15
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEODr. Mark A. Goldsmith M.D., Ph.D.
- Founded2014
- Employees883
- Websitewww.revmed.com
Identifiers
- ISINUS76155X1000
- FIGIBBG00829F4P8
- LEI549300JU3X0LBCQ65892
- CUSIP76155X100
- CIK0001628171